SU1699433A1 - Method for treating peritonitis - Google Patents
Method for treating peritonitis Download PDFInfo
- Publication number
- SU1699433A1 SU1699433A1 SU894705364A SU4705364A SU1699433A1 SU 1699433 A1 SU1699433 A1 SU 1699433A1 SU 894705364 A SU894705364 A SU 894705364A SU 4705364 A SU4705364 A SU 4705364A SU 1699433 A1 SU1699433 A1 SU 1699433A1
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- patient
- day
- days
- protein
- connection
- Prior art date
Links
- 206010034674 peritonitis Diseases 0.000 title claims abstract description 6
- 238000000034 method Methods 0.000 title claims abstract 3
- 210000001363 mesenteric artery superior Anatomy 0.000 claims abstract description 3
- 238000011287 therapeutic dose Methods 0.000 claims abstract 2
- 210000000683 abdominal cavity Anatomy 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- 238000001361 intraarterial administration Methods 0.000 claims description 4
- 230000003247 decreasing effect Effects 0.000 claims description 3
- 230000000721 bacterilogical effect Effects 0.000 claims description 2
- 230000008855 peristalsis Effects 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 208000007502 anemia Diseases 0.000 claims 1
- 238000009534 blood test Methods 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 abstract description 3
- JGONUWOERJCFMF-UHFFFAOYSA-N 2-hydroxy-5-(3-methylbut-2-enyl)-6-prop-1-en-2-ylcyclohepta-2,4,6-trien-1-one Chemical compound CC(C)=CCC1=CC=C(O)C(=O)C=C1C(C)=C JGONUWOERJCFMF-UHFFFAOYSA-N 0.000 abstract 2
- UEASBNMLRVSIRE-UHFFFAOYSA-N Procerine Natural products CC(C(=O)C)C(=O)OC1CCN2CC(O)C(CO)C12 UEASBNMLRVSIRE-UHFFFAOYSA-N 0.000 abstract 1
- 238000001802 infusion Methods 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 210000003405 ileum Anatomy 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010021079 Hypopnoea Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 208000011316 hemodynamic instability Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229940096441 metronidazole 500 mg Drugs 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 230000001020 rhythmical effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Изобретение относитс к ургентной хирургии и может быть использовано дл лечени острого перитонита. Целью изобретени вл етс предупреждение осложнений . Способ осуществл етс путем введени в верхнюю брыжеечную артерию реополюглюкина, гемодеза и прозернина в терапевтических дозах под давлением 150- 200 мм рт.ст. со скоростью 70-75 кап/мин по 2-3 раза в 1 сут в течение 2-4 сут.This invention relates to surgery and can be used to treat acute peritonitis. The aim of the invention is to prevent complications. The method is carried out by administering reopolyuglyukin, hemodez, and procerin in therapeutic doses under a pressure of 150-200 mm Hg into the superior mesenteric artery. with a speed of 70-75 drops / min 2-3 times in 1 day for 2-4 days.
Description
Изобретение относитс к ургентной хирургии и может быть использовано дл лечени острого перитонита.This invention relates to surgery and can be used to treat acute peritonitis.
Целью изобретени вл етс предупреждение осложнений.NThe aim of the invention is to prevent complications.
Пример. Больной Ю.М,, 28 лет, поступил в общехирургическое отделение из психиатрической больницы с жалобами на боли в животе. Со слов сопровождающих у больного в течение недели отмечаютс боли в животе, особенно сильно выраженные в последние трое суток, тошнота, неоднократна рвота. В св зи с психическим статусом контакт с больным затруднен. Объективно: общее состо ние т желое. На вопросы не отвечает, не ориентируетс в окружающей среде. Кожные покровы бледноватые. Тоны сердца приглушены, пульс 110 уд/мин, ритмичный , АД 110/75 мм рт.ст. В легких везикул рное дыхание, хрипов нет, частота дыхательных движений до 24 в 1 мин, дыхание поверхностное, грудной тип. Язык суховат , обложен белым налетом. Живот резко напр жен, болезненный во всех отделах, в акте дыхани не участвует. Печеночна тупость уменьшена, печень и селезенка неExample. Patient Y.M., 28 years old, was admitted to the general surgical department of a psychiatric hospital with complaints of abdominal pain. According to the accompanying patient, during the week there are abdominal pains, especially severe in the last three days, nausea, repeated vomiting. Contact with the patient is difficult due to mental status. Objectively: the general condition is severe. Does not answer questions, does not focus on the environment. The skin is pale. Muffled heart sounds, pulse 110 beats / min, rhythmic, BP 110/75 mm Hg In the lungs, vesicular breathing, no wheezing, respiratory rate up to 24 in 1 min, shallow breathing, chest type. Tongue dryish, white coated. The abdomen is sharply strained, painful in all departments, is not involved in the act of breathing. Hepatic dullness reduced, liver and spleen not
пальпируютс , перистальтика кишечника не выслушиваетс . Симптом Щеткина--Блюм- берга резко положительный во всех отделах . При рентгенологическом исследовании вы влено наличие свободного газа у купола диафрагмы. Выставлен диагноз перфора- тивна зва 12-перстной кишки, перитонит После кратковременной интенсивной и инфузионной терапии больному произведено оперативное вмешательство. При операции вы влено наличие в брюшной полости до 1 л гнойно-фибринозного выпота с запахом кишечной палочки. Источником перитонита были перфоративные отверсти в терминальном отделе подвздошной кишки на рассто нии 35-40 см от Баугиневой заслонки , размером 0,,8 и 0,6x0,6 см. Произведено ушивание перфоративной звы подвздошной кишки, интубаци тонкой кишки назоинтестинальным зондом на прот жении до 1,5 м от св зки Трейца. Дренирование брюшной полости дл введени антибиотиков. Произведен тщательный ин- траоперационный лаваж брюшной полости 10 л раствора Рингера с добавлением в последнюю порцию раствора диоксидина,palpable, intestinal motility is not heard. The symptom of Shchetkin - Blumberg is sharply positive in all departments. X-ray examination revealed the presence of free gas in the dome of the diaphragm. A diagnosis of perforation of the duodenal ulcer, peritonitis was made. After a short-term intensive and infusion therapy, the patient underwent surgery. During the operation, the presence in the abdominal cavity of up to 1 l of purulent-fibrinous effusion with the smell of E. coli was revealed. The source of peritonitis was perforating holes in the terminal ileum at a distance of 35-40 cm from the Bauginov valve, 0, 8 and 0.6x0.6 cm in size. The perforation of the ileum ulcer was sutured, and the small intestine intubation was carried out with a nasi-intestinal probe during 1.5 m from the Treitz link. Drainage of the abdominal cavity for the administration of antibiotics. A thorough intraoperative lavage of the abdominal cavity of 10 l of Ringer's solution with the addition of dioxidine solution,
слcl
сwith
о ю ю 00 CJabout you 00 CJ
метронидазола и канамицина. Послойное ушивание послеоперационной раны.metronidazole and kanamycin. Layer wound closure.
Состо ние больного в раннем послеоперационном периоде крайне т желое, отмечалась нестабильность гемодинамики, тахикарди до 130-140 уд/мин, АД 100/80- 130/90 мм рт.ст,, ЦВД 0 мм вод.ст. В брюшную полость вводили антибиотики с учетом результатов экспресс-бактериоскопии и бактериологического исследовани - кана- мицин по 1 г 3 раза в сутки, метронидазол по 500 мг 3 раза в сутки и 1 %-ный диоксидин 60 мл. После экстубации 22 марта 1989 г., учитыва отсутствие перистальтики кишечника , произведена с целью проведени ре- гионарной внутриартериальной инфузии лекарственных веществ катетеризаци верхней брыжеечной артерии и начала ка- тетерна терапи с последовательным введением в просвет верхней брыжеечной артерии сначала реополиглюкина 400 мл, затем гемодеза 800 мл и прозернина 1 мл со скоростью 70 кап/мин под давлением 200 мм рт.ст. непрерывно. На прот жении первых суток осуществлено два таких сеанса. Общий объем внутриартериальной инфузии 2,4л.The condition of the patient in the early postoperative period is extremely heavy, hemodynamic instability, tachycardia up to 130-140 beats / min, blood pressure 100 / 80-130/90 mm Hg, CVP 0 mm water column. Antibiotics were introduced into the abdominal cavity, taking into account the results of rapid bacterioscopy and bacteriological examination, kanamycin 1 g 3 times a day, metronidazole 500 mg 3 times a day and 1% dioxidine 60 ml. After extubation on March 22, 1989, taking into account the absence of intestinal peristalsis, a catheterization of the superior mesenteric artery was performed with the aim of conducting a regional intraarterial infusion of medicinal substances and the beginning of catheteric therapy with sequential introduction of reopolyglucin 400 ml, then hemodez 800 ml and procerina 1 ml at a speed of 70 drops / min under a pressure of 200 mm Hg continuously. During the first day, two such sessions were carried out. The total amount of intra-arterial infusion 2,4l.
В результате проводимой внутриартериальной терапии констатирована положительна динамика, выражавша с в виде снижени признаков интоксикации -уреже- ни пульса, снижени температуры, У больного по вилс жидкий стул до 2 л а сутки, снизились концентраци средних молекул с 361/мл до 164 в конце первых суток прове- дени катетерной терапии, индекс Кальф- Калифа снизилс с 23 до 12,4. С 24 мартаAs a result of intraarterial therapy, a positive dynamics was found, expressed in the form of a decrease in signs of intoxication, a pulse rate, a decrease in temperature, the patient had loose stools up to 2 liters per day, the concentration of medium molecules decreased from 361 / ml to 164 at the end of the first days of catheter therapy, the Kalf-Kalif index decreased from 23 to 12.4. From March 24
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU894705364A SU1699433A1 (en) | 1989-06-29 | 1989-06-29 | Method for treating peritonitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU894705364A SU1699433A1 (en) | 1989-06-29 | 1989-06-29 | Method for treating peritonitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SU1699433A1 true SU1699433A1 (en) | 1991-12-23 |
Family
ID=21454249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU894705364A SU1699433A1 (en) | 1989-06-29 | 1989-06-29 | Method for treating peritonitis |
Country Status (1)
| Country | Link |
|---|---|
| SU (1) | SU1699433A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA007473B1 (en) * | 2004-06-07 | 2006-10-27 | Алексей Михайлович Федорук | Method for treating pancreatitis |
-
1989
- 1989-06-29 SU SU894705364A patent/SU1699433A1/en active
Non-Patent Citations (1)
| Title |
|---|
| БМЭ, 1980, т.12, с 26-29. * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA007473B1 (en) * | 2004-06-07 | 2006-10-27 | Алексей Михайлович Федорук | Method for treating pancreatitis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SU1699433A1 (en) | Method for treating peritonitis | |
| RU2000788C1 (en) | Method for treatment of self-poisoning | |
| RU2154505C1 (en) | Method for treating abdominal cavity in acute peritonitis cases | |
| RU2132192C1 (en) | Method of human organism adaptation in pathological processes accompanying with metabolic disorders | |
| RU2199326C2 (en) | Treating endotoxicosis in patients with destructive pancreatitis | |
| RU2069559C1 (en) | Method for performing sympathetic ganglionic block | |
| RU2190412C2 (en) | Method for body detoxication | |
| RU2029504C1 (en) | Method for preventing post-operative complications | |
| RU2122345C1 (en) | Method of post-operation enteric diet nutrition | |
| RU2147899C1 (en) | Method for stimulating intestine peristalsis in postoperative period | |
| RU2709113C1 (en) | Method of treating intestinal failure with an oxygenated saline enteral solution | |
| RU2851243C1 (en) | Method of endomesenteric lymphotropic therapy in treatment of widespread peritonitis in postoperative period | |
| RU2266738C2 (en) | Method for treating endotoxicosis cases accompanying pyoseptic small pelvis diseases | |
| RU2092107C1 (en) | Method for treatment hepatic insufficiency in patients affected with ascites | |
| RU2817988C1 (en) | Method for recovery of functional state of liver in severe acute pancreatitis | |
| UA11994U (en) | Method for treating acute erosion and ulcer of intestine and stomach in acute pancreatitis | |
| RU2683939C1 (en) | Method of intravenous infusion of sodium hypochlorite, activation of glycolysis, treatment of benign and malignant neoplasms, higher effectiveness of chemotherapy of malignant neoplasms, treatment of secondary immune deficiency in generalized bacterial and viral infections | |
| RU2164153C1 (en) | Method for treatment of dumping syndrome | |
| RU2111770C1 (en) | Method for anesthetization during operation of cesarean section | |
| RU2188645C2 (en) | Method for making eneterosorption | |
| RU1811858C (en) | Method of detoxification of organism | |
| RU2245159C1 (en) | Method for treating surgical endotoxicosis | |
| RU2213523C1 (en) | Method for treating patients for cholangitis | |
| RU2428191C1 (en) | Method of local dosed ozone therapy following gall bladder and/or bile passages surgery | |
| RU2348404C1 (en) | Method of treatment of acute destructive pancreatitis |